Herbert Ezugha
Neurology with Special Qualifications in Child Neurology · Henderson, NVNPI 1871758649
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by UCB, Inc. at 30.2% of the total. Reporting peaked in 2023 at $735 and has fallen 83.5% since, to $121 in 2025.
Across 81 payments — averaging $33.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$823
- Livanova USA, Inc.$458
- Immedica Pharma US, Inc.$214
- Sunovion Pharmaceuticals Inc.$135
- Jazz Pharmaceuticals Inc.$120
- Aquestive Therapeutics, Inc.$115
- plus $861 from 19 others
What the payments were for
- Travel & lodging$1696%
- Food & beverage$2,54093%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 23 | $823 |
| Livanova USA, Inc. | 5 | $458 |
| Immedica Pharma US, Inc. | 6 | $214 |
| Sunovion Pharmaceuticals Inc. | 8 | $135 |
| Jazz Pharmaceuticals Inc. | 4 | $120 |
| Aquestive Therapeutics, Inc. | 1 | $115 |
| Biomarin Pharmaceutical Inc. | 2 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $96 |
| SK Life Science, Inc. | 3 | $95 |
| Neurelis, Inc. | 4 | $87 |
| PTC Therapeutics, Inc. | 2 | $51 |
| Eisai Inc. | 2 | $47 |
| Acadia Pharmaceuticals Inc | 2 | $45 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $42 |
| Greenwich Biosciences, Inc. | 2 | $41 |
| Sarepta Therapeutics, Inc. | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Tersera Therapeutics LLC | 1 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $27 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| AstraZeneca | 1 | $20 |
| Travere Therapeutics, Inc. | 3 | $16 |
| Cranial Technologies, Inc | 1 | $16 |
| Metacel Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$169
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$164
- Fintepla$125
- SYMPAZAN$115
- Briviact$100
How this compares
Too few neurology with special qualifications in child neurology providers in Nevadato place this figure against a meaningful peer group, so we don't.
Other neurology with special qualifications in child neurology in Henderson
- Roshan RajaHenderson$4K
- Monica ChaconHenderson$2K
- Gerardo RodriguezReno$11K
- Devraj ChavdaLas Vegas$7K
- Colin NguyenReno$4K
- Mei JiangLas Vegas$4K
- Stacey KnoblerReno$3K
- Rooman AhadLas Vegas$2K
- Tiffani McDonoughReno$286
- Shanti ThirumalaiReno$226
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.